慢性乙型肝炎抗病毒治疗与血清HBsAg和HBcrAg水平的变化

目的：探讨核苷（酸）类抗病毒治疗与慢性乙型肝炎（CHB）患者血清HBsAg和HBcrAg水平的变化。方法：108例CHB患者入选本研究，其中HBeAg阳性患者分别进入抗病毒组46例和非抗病毒组20例，HBeAg阴性患者进入抗病毒组31例和非抗病毒组11例。血清HBsAg和HBcrAg分别采用化学发光微粒免疫法和化学发光酶免疫法检测。结果：无论HBeAg阳性或阴性患者，抗病毒组与非抗病毒组随访时间差异均无统计学意义（P＞0.05）；抗病毒组随访起点与终点血清HBsAg和HBcrAg水平差异均有统计学意义（均P＜0.05），非抗病毒组随访起点与终点血清HBsAg和HBcrAg水平差异均无统计学意义（均P＞0.05）；抗病毒组与非抗病毒组从随访起点到终点血清HBsAg下降幅度和下降比例差异均无统计学意义（均P＞0.05），从随访起点到终点血清HBcrAg下降幅度和下降比例差异均有统计学意义（P＜0.05）。结论：CHB患者的抗病毒治疗能导致显著的血清HBsAg和HBcrAg下降，但只能获得显著的血清HBcrAg下降幅度和下降比例。

Nucleos(t)ides antiviral therapy and the changes of serum HBsAg and HBcrAg levels in patients with chronic hepatitis B

Objective: To investigate the changes of serum hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) levels in patients with chronic hepatitis B treated with nucleos(t)ides antiviral therapy. Methods: One hundred and eight patients of chronic hepatitis B patients were enrolled in this study, 46 patients and 20 patients of HBeAg-positive patients respectively were divided into the antiviral group and the non-antiviral group, 31 patients and 11 patients of HBeAg-negative patients respectively were into the antiviral group and the non-antiviral group. Serum HBsAg and HBcrAg levels were respectively detected by chemiluminescence microparticle immunoassay and chemiluminescence enzyme immunoassay. Results: In both HBeAg-positive and HBeAg-negative patients, the differences of the follow-up time between antiviral and non-antiviral group were no statistically significant (P>0.05); the differences of serum HBsAg and HBcrAg levels between the follow-up start and the follow-up end were statistically significant in antiviral group (P<0.05), and which of serum HBsAg and HBcrAg levels between the follow-up start and the follow-up end were not statistically significant in non-antiviral group (P>0.05); the differences of serum HBsAg levels decline extent and proportion from follow-up start to the follow-up end between antiviral and non-antiviral group were not statistically significant (P>0.05), and which of HBcrAg decline extent and proportion from follow-up start to the follow-up end between antiviral and non-antiviral group were statistically significant. Conclusion: The antiviral therapy of CHB patients can lead to the significant decrease of serum HBsAg and HBcrAg levels, but can only get the significant decline extent and proportion of serum HBcrAg.